Neurocrine Biosciences has sent off an NDA for its experimental med earlier than analysts had reckoned as it seeks U.S. approval for treating twitches of the…

Weak Phase III data have dealt a blow to Vectura’s hopes of seeing Flutiform approved for use in chronic obstructive pulmonary disease patients.

The Asian unit of perpetual life science backer OrbiMed has led a modest $9.7 million first round for biotech CBT Pharmaceuticals as it looks to build up its c…

Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.

Ferring Pharmaceuticals has secured the rights to a Phase III treatment of radicular leg pain outside of Japan from Seikagaku.

Since Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver and…

TG Therapeutics got orphan drug designation from the FDA for both its clinical candidates this week.

Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has…